Novavax, an American vaccine research and development company, expects to provide a new coronavirus vaccine customized for the Omicron BA.4 and BA.5 mutant strains in the fourth quarter of this year.

The Paper reporter Nan Boyi

US vaccine research and development company Novavax

US vaccine research and development company Novavax (Novavax) is expected to provide Omicron BA.4 and BA.5 in the fourth quarter of this year. new crown vaccine tailored for mutated strains.

Reuters reported that Novavax said on Friday (July 1) that researchers are accelerating the development of vaccines to target these two mutant strains.

Omicron BA.4 and BA.5 are currently circulating new coronavirus mutant strains. According to the latest statistics from the World Health Organization , the two strains have become the main strains in the world. The U.S. Food and Drug Administration (FDA) recommended on June 30 that COVID-19 vaccine manufacturers update the vaccine design and ensure that the vaccine booster dose launched in the fall contains protection against these two mutant strains.

Novavax said more clinical data on vaccination with the Omicron BA.4 and BA.5 tailored vaccines will be available later in the summer or fall.

Editor in charge: Liu Dong Picture editor: Zhang Tongze